Isatuximab单药用于高致敏肾移植候选者脱敏治疗
这项开放标签单臂1/2期研究评估了Isatuximab在等待肾移植的高致敏患者中的安全性、药代动力学和初步疗效。23例患者接受每周10 mg/kg共4周后每2周一次共8周的治疗,总体缓解率在cPRA≥99.90%组为83.3%、80.00%至<99.90%组为81.8%,抗HLA抗体下降可持续26周,但cPRA降至目标水平者仅9/23(39%)。
要点
- Isatuximab耐受良好,可使CD38+浆母细胞、浆细胞和NK细胞下降,并显著减少产生HLA特异性IgG的记忆B细胞。
- 总体缓解率在cPRA≥99.90%组为83.3%、80.00%至<99.90%组为81.8%,多数缓解者抗HLA抗体下降维持26周。
- 仅9/23(39%)患者cPRA降至目标水平,脱敏活性为部分性。
核心结论
- Isatuximab耐受良好,可导致抗HLA抗体持久下降,具有部分脱敏活性。
- Isatuximab可作为现有脱敏方案的辅助治疗选项进一步研究。
研究设计与样本
- 开放标签单臂1/2期研究,评估Isatuximab在等待肾移植患者中的安全性、药代动力学和初步疗效。
- 共23例患者,队列A(cPRA≥99.90%)12例,队列B(cPRA 80.00%至<99.90%)11例。
- 给药方案为Isatuximab 10 mg/kg每周一次共4周,然后每2周一次共8周。
主要发现
- Isatuximab耐受良好,药代动力学和药效学特征显示暴露量与多发性骨髓瘤试验相似。
- 治疗导致CD38+浆母细胞、浆细胞和NK细胞下降,并显著减少产生HLA特异性IgG的记忆B细胞。
- 基于预设复合脱敏终点的总体缓解率在队列A为83.3%、队列B为81.8%。
- 多数缓解者抗HLA抗体下降在末次给药后维持26周。
- 总体cPRA值受影响较小,仅9/23(39%)患者cPRA降至目标水平;截至研究截止(中位随访68周),6例患者收到移植邀请,其中4例接受。
关键数值与推荐
- 高致敏定义为cPRA≥80.00%,其中cPRA≥99.90%者尤其难以获得移植。
- 总体缓解率:队列A(cPRA≥99.90%)83.3%,队列B(cPRA 80.00%至<99.90%)81.8%。
- cPRA降至目标水平者仅9/23(39%)。
临床怎么用
- Isatuximab可作为高致敏肾移植候选者脱敏的辅助治疗选择,但需注意cPRA降至目标水平的比例有限。
- 治疗期间应监测CD38+浆细胞和抗HLA抗体变化,评估脱敏反应。
局限性
- 开放标签单臂设计,样本量小(23例),缺乏对照组。
- 随访期间仅6例收到移植邀请,移植结局数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity. The short treatment period and long follow-up of this study allowed for the understanding of the mechanism and timing for any antibody rebound. Isatuximab could be further investigated as an option for adjunct therapy to existing desensitization for patients on the kidney transplant waitlist. BACKGROUND: Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase the chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. METHODS: This was an open-label single-arm phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, cohorts A and B, which enrolled cPRA ≥99.90% and 80.00% to <99.90%, respectively. RESULTS: Twenty-three patients (12 cohort A, 11 cohort B) received isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks. Isatuximab was well tolerated with pharmacokinetic and pharmacodynamic profiles that indicated similar exposure to multiple myeloma trials. It resulted in decreases in CD38 + plasmablasts, plasma cells, and NK cells and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, on the basis of a predefined composite desensitization end point, was 83.3% and 81.8% in cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall, cPRA values were minimally affected, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cutoff (median follow-up of 68 weeks), six patients received transplant offers, of which four were accepted. CONCLUSIONS: In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity. CLINICAL TRIAL REGISTRATION NUMBER: NCT04294459 .
引用
- Vincenti F, Bestard O, Brar A, et al. Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant. J Am Soc Nephrol. 2023. PMID: 38147137. doi:10.1681/ASN.0000000000000287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。